Connection

Co-Authors

This is a "connection" page, showing publications co-authored by THOMAS CATE and ROBERT COUCH.
Connection Strength

1.109
  1. Improvement of inactivated influenza virus vaccines. J Infect Dis. 1997 Aug; 176 Suppl 1:S38-44.
    View in: PubMed
    Score: 0.152
  2. Evaluation of age-related differences in the immunogenicity of a G9 H9N2 influenza vaccine. Vaccine. 2011 Oct 19; 29(45):8066-72.
    View in: PubMed
    Score: 0.101
  3. A high dosage influenza vaccine induced significantly more neuraminidase antibody than standard vaccine among elderly subjects. Vaccine. 2010 Feb 25; 28(9):2076-9.
    View in: PubMed
    Score: 0.090
  4. Contrasting effects of type I interferon as a mucosal adjuvant for influenza vaccine in mice and humans. Vaccine. 2009 Aug 27; 27(39):5344-8.
    View in: PubMed
    Score: 0.087
  5. Increasing doses of an inactivated influenza A/H1N1 vaccine induce increasing levels of cross-reacting antibody to subsequent, antigenically different, variants. J Infect Dis. 2008 Oct 01; 198(7):1016-8.
    View in: PubMed
    Score: 0.083
  6. Safety and immunogenicity of a high dosage trivalent influenza vaccine among elderly subjects. Vaccine. 2007 Nov 01; 25(44):7656-63.
    View in: PubMed
    Score: 0.077
  7. A dose-response evaluation of inactivated influenza vaccine given intranasally and intramuscularly to healthy young adults. Vaccine. 2007 Jul 20; 25(29):5367-73.
    View in: PubMed
    Score: 0.075
  8. Safety and immunogenicity of nonadjuvanted and MF59-adjuvanted influenza A/H9N2 vaccine preparations. Clin Infect Dis. 2006 Nov 01; 43(9):1135-42.
    View in: PubMed
    Score: 0.072
  9. Safety of high doses of influenza vaccine and effect on antibody responses in elderly persons. Arch Intern Med. 2006 May 22; 166(10):1121-7.
    View in: PubMed
    Score: 0.070
  10. Immunization against influenza: comparison of various topical and parenteral regimens containing inactivated and/or live attenuated vaccines in healthy adults. J Infect Dis. 2001 Jan 15; 183(2):329-332.
    View in: PubMed
    Score: 0.048
  11. Cytotoxic T lymphocyte responses of infants after natural infection or immunization with live cold-recombinant or inactivated influenza A virus vaccine. J Med Virol. 1996 Oct; 50(2):105-11.
    View in: PubMed
    Score: 0.036
  12. Increasing doses of purified influenza virus hemagglutinin and subvirion vaccines enhance antibody responses in the elderly. Clin Diagn Lab Immunol. 1996 Sep; 3(5):507-10.
    View in: PubMed
    Score: 0.036
  13. Comparison of trivalent cold-adapted recombinant (CR) influenza virus vaccine with monovalent CR vaccines in healthy unselected adults. J Infect Dis. 1995 Jul; 172(1):253-7.
    View in: PubMed
    Score: 0.033
  14. Influenza A subtype cross-protection after immunization of outbred mice with a purified chimeric NS1/HA2 influenza virus protein. Vaccine. 1994 Nov; 12(14):1340-8.
    View in: PubMed
    Score: 0.032
  15. Vaccination with inactivated influenza A virus during pregnancy protects neonatal mice against lethal challenge by influenza A viruses representing three subtypes. J Virol. 1990 Mar; 64(3):1370-4.
    View in: PubMed
    Score: 0.023
  16. Efficacy of sequential annual vaccination with inactivated influenza virus vaccine. Am J Epidemiol. 1988 Feb; 127(2):353-64.
    View in: PubMed
    Score: 0.020
  17. Dose-related safety and immunogenicity of a trivalent baculovirus-expressed influenza-virus hemagglutinin vaccine in elderly adults. J Infect Dis. 2006 May 01; 193(9):1223-8.
    View in: PubMed
    Score: 0.017
  18. Genetic approaches to attenuation of influenza A viruses for man. Philos Trans R Soc Lond B Biol Sci. 1980 Feb 25; 288(1029):401-15.
    View in: PubMed
    Score: 0.011
  19. Temperature-sensitive mutants of influenza A virus: evaluation of the A/Victoria/75-ts-1A2 temperature-sensitive recombinant virus in seronegative adult volunteers. Infect Immun. 1979 Feb; 23(2):249-52.
    View in: PubMed
    Score: 0.011
  20. Efficacy of repeated annual immunization with inactivated influenza virus vaccines over a five year period. Vaccine. 1997 Jul; 15(10):1114-22.
    View in: PubMed
    Score: 0.009
  21. High doses of purified influenza A virus hemagglutinin significantly augment serum and nasal secretion antibody responses in healthy young adults. J Clin Microbiol. 1994 Oct; 32(10):2468-73.
    View in: PubMed
    Score: 0.008
  22. Trivalent attenuated cold-adapted influenza virus vaccine: reduced viral shedding and serum antibody responses in susceptible adults. J Infect Dis. 1993 Feb; 167(2):305-11.
    View in: PubMed
    Score: 0.007
  23. Cold recombinant influenza B/Texas/1/84 vaccine virus (CRB 87): attenuation, immunogenicity, and efficacy against homotypic challenge. J Infect Dis. 1990 Jan; 161(1):22-6.
    View in: PubMed
    Score: 0.006
  24. Evaluation of influenza A/Hong Kong/123/77 (H1N1) ts-1A2 and cold-adapted recombinant viruses in seronegative adult volunteers. Infect Immun. 1980 Aug; 29(2):348-55.
    View in: PubMed
    Score: 0.003
  25. Temperature-sensitive mutants of influenza A virus: evaluation of A/Victoria/3/75-ts-1[E] recombinant viruses in volunteers. Infect Immun. 1978 Jun; 20(3):671-7.
    View in: PubMed
    Score: 0.003
Connection Strength

The connection strength for concepts is the sum of the scores for each matching publication.

Publication scores are based on many factors, including how long ago they were written and whether the person is a first or senior author.